Theratechnologies Announces Financial Results for First Quarter of 2018

- April 5th, 2018

Theratechnologies (TSX:TH) announced its financial results for the first quarter ended February 28, 2018. As quoted in the press release: “We have every reason to be excited and proud of where we are today with the recent approval of Trogarzo™. We are seeing strong interest from both physicians and patients. As Trogarzo™ will soon be … Continued

Theratechnologies (TSX:TH) announced its financial results for the first quarter ended February 28, 2018.

As quoted in the press release:

“We have every reason to be excited and proud of where we are today with the recent approval of Trogarzo™. We are seeing strong interest from both physicians and patients. As Trogarzo™ will soon be commercially available, our fully-trained sales force started calling on more than 5,000 physicians who treat the vast majority of people living with multidrug resistant HIV. Moreover, we had our strongest first quarter ever in terms of net sales of EGRIFTA®,” said Luc Tanguay, President and CEO, Theratechnologies Inc.

Consolidated revenue for the three-month period ended February 28, 2018 was $10,218,000 compared to $9,035,000 in the three-month period ended February 28, 2017. Revenue generated from net sales increased by 13.1% in the first quarter of 2018 compared to the comparable period in fiscal 2017, due to higher unit volumes and prices, partially offset by exchange rate fluctuations and higher discounts due to changes in the mix of private payors versus government drug reimbursement plans.

Click here to read the full press release.

We found the top performing pharma stocks to watch this year

Find out more in our report
 

Leave a Reply

Your email address will not be published. Required fields are marked *